IDEXX(IDXX)
Search documents
Pricier vet care: Fewer visits but still many $11,000 surgeries
Fortune· 2026-03-22 21:53
It’s exceedingly expensive to own a pet, prompting owners to delay veterinary visits or reconsider adopting one in the first place. Yet, animal health companies’ earnings keep growing.That’s down to the unwavering love between owners and their pets.While some owners might extend the time between their pets’ annual wellness visits to save money, they’ll shell out when their darling is truly sick or hurt, and that care is often the most expensive — and lucrative.Last year, Matthew Joseph, a 41-year-old New Yo ...
Is IDEXX Laboratories Stock Outperforming the S&P 500?
Yahoo Finance· 2026-03-16 08:19
Company Overview - IDEXX Laboratories, Inc. is a leader in veterinary diagnostics, software, and water testing solutions, based in Westbrook, Maine, with a market cap of $45.7 billion [1] - The company develops diagnostic instruments, test kits, software, and laboratory services for veterinarians, farmers, and laboratories to monitor animal health and detect diseases [1] Market Position - IDEXX is classified as a "large-cap stock" and is recognized as a market leader in veterinary diagnostics, benefiting from strong brand recognition and a large installed base of diagnostic instruments [2] - The company's solutions are utilized in over 175 countries, indicating a robust global presence [2] Stock Performance - Shares of IDEXX have decreased by 25.5% from their 52-week high of $769.98 and have dipped 18.5% over the past three months, underperforming the S&P 500 Index's decline of 2.9% [3] - Over the past six months, IDEXX shares are down 10.5%, while the S&P 500 has shown marginal returns [5] - Despite recent declines, IDEXX stock has increased by 41.2% over the past 52 weeks, outperforming the S&P 500's 20.1% increase during the same period [5] Recent Financial Performance - On February 2, IDEXX reported a strong fourth-quarter 2025 performance with revenue of $1.1 billion and adjusted earnings of $3.08 per share, both exceeding analyst expectations [6] - However, the gross margin of 60.3% fell short of the consensus forecast of 61% [6] Competitive Landscape - IDEXX has outperformed its main competitor, Zoetis Inc., which has seen a decline of 27.8% over the past 52 weeks and 22% over the past six months [7] - Analysts maintain a cautiously optimistic outlook for IDEXX, with a consensus rating of "Moderate Buy" and a mean price target of $773.58, representing a 34.8% premium to current levels [7]
Is IDEXX Laboratories, Inc. (IDXX) A Good Stock To Buy?
Yahoo Finance· 2026-03-14 23:45
Core Thesis - IDEXX Laboratories, Inc. is positioned for long-term growth in the pet healthcare sector, driven by increasing demand for veterinary diagnostics as pet owners seek advanced care for their animals [3][8]. Financial Performance - The company's diagnostic business is highly profitable, supported by recurring revenue and strong margins, contributing to a durable growth platform [4]. - IDEXX has consistently demonstrated robust financial performance, with earnings per share growth ranking in the top 10% of all companies over recent quarters and years [4]. - The share price has gained 60.4% over the past 52 weeks, placing it among the top 10% of stocks on a relative strength basis [6]. Market Trends - The aging cohort of pets born during the 2020 pandemic puppy boom adds a structural tailwind, as these animals will require more frequent veterinary visits and diagnostic testing [5]. - Pet owners are continuing to spend more per animal, further driving demand for veterinary services [5]. Investment Opportunity - IDEXX Laboratories offers an attractive opportunity for investors to capture both growth and consistent profitability in the pet healthcare sector [7]. - The company's outlook remains positive, making its shares a compelling buy for those seeking exposure to structural growth in veterinary diagnostics [8].
IDEXX Laboratories, Inc. (IDXX) Presents at 47th Annual Raymond James Institutional Investor Conference - Slideshow (NASDAQ:IDXX) 2026-03-10
Seeking Alpha· 2026-03-10 23:12
Group 1 - The company is responsible for the development of transcript-related projects [1] - It publishes thousands of quarterly earnings calls per quarter and is expanding its coverage [1]
IDEXX Laboratories Stock Climbs 39.4% in a Year: What's Driving It?
ZACKS· 2026-03-09 18:06
Core Insights - IDEXX Laboratories (IDXX) has experienced a significant stock price increase of 39.4% over the past year, outperforming the industry which saw a decline of 4.3% and the S&P 500 Composite's return of 23.1% [1] - The company holds a Zacks Rank 3 (Hold) and is benefiting from strong recurring revenues in its Companion Animal Group (CAG) Diagnostics, driven by improved net price realization and solid volume growth [1] Financial Performance - CAG Diagnostics' recurring revenues grew organically by 10% in Q4 2025, supported by volume growth and average global net price improvement [5][9] - The Zacks Consensus Estimate projects earnings per share (EPS) for 2026 and 2027 to increase by 11.2% and 12.4% year-over-year, reaching $14.55 and $16.36 respectively [13] - Revenues are expected to grow by 8.6% to $4.67 billion in 2026 and reach $5.09 billion in 2027, implying an 8.9% increase [13] Business Expansion and Innovation - IDEXX is expanding its international commercial footprint, enhancing clinic workflows through software solutions that promote greater utilization of diagnostics [2][10] - The company has launched several innovations, including the Cancer Dx diagnostic panel and the inVue Dx cellular analyzer, which are gaining commercial traction [6][10] - The software ecosystem, including practice information management systems (PIMS) and Vello tools, is crucial for improving clinic workflows and driving growth [11] Market Presence - IDEXX Laboratories operates in over 175 countries, focusing on innovation and customer service as key components of its long-term value creation strategy [4] - The company’s commercial strategies are tailored to regional dynamics, supported by strong Reference Laboratory networks [10] Challenges - The U.S. clinical visit growth is facing constraints due to staffing challenges at veterinary clinics and broader macroeconomic impacts on consumers [12]
Is This the Right Time to Retain IDXX Stock in Your Portfolio?
ZACKS· 2026-03-06 15:42
Core Insights - IDEXX Laboratories, Inc. (IDXX) is focusing on innovation within its Companion Animal Group (CAG), leading to a strong portfolio of products and services that support customer needs [1] - The company is experiencing significant growth in global commercial capabilities, particularly in CAG Diagnostics, despite facing challenges related to solvency and macroeconomic pressures [1] Financial Performance - Over the past year, IDEXX's stock has increased by 43.9%, outperforming the industry's decline of 4.2% and the S&P 500's growth of 21.9% [2] - IDEXX has a market capitalization of $51.7 billion and an earnings yield of 2.2%, significantly higher than the industry's -0.7% yield [2] - The company has consistently surpassed earnings estimates over the last four quarters, achieving an average surprise of 6.11% [2] Business Growth - IDEXX's CAG business continues to perform well, with innovations like the Cancer Dx diagnostic panel and inVue Dx cellular analyzer gaining traction [3] - In Q4 2025, CAG Diagnostics' recurring revenues grew organically by 10%, driven by volume growth and improved pricing [4] - Veterinary software and diagnostic imaging revenues also saw a 13% organic increase, supported by the company's vertical SaaS strategy [4] Global Expansion - IDEXX is strategically investing in regions with strong customer readiness and growth potential, planning to expand into three international markets by early 2026 [6][8] - The company is preparing to introduce the Cancer Dx panel to international markets in Q1 2026, enhancing its position in veterinary cancer diagnostics [9] Software Innovation - IDEXX's cloud-based solutions are enhancing clinic workflows and increasing the utilization of diagnostics, with strong performance in practice information management systems (PIMS) [10] - The integration of tools like Vello with IDEXX's diagnostics ecosystem is expected to drive long-term growth [10] Solvency and Challenges - As of Q4 2025, IDEXX had cash and cash equivalents of $180.1 million against $473 million in short-term debt and $375 million in long-term debt, indicating a challenging solvency position [11] - The company anticipates a net price improvement of approximately 3.5% in the U.S. for 2026, but expects a decline of 2% in same-store clinical visit growth due to macroeconomic constraints [12] - Sustained inflationary pressures may pose challenges in managing costs of revenues and operating expenses [12] Future Outlook - The Zacks Consensus Estimate for IDEXX's 2026 EPS has increased by 0.6% to $14.54, with projected revenues of $4.67 billion, indicating an 8.6% rise from the previous year [13]
Why Is Idexx (IDXX) Up 0.5% Since Last Earnings Report?
ZACKS· 2026-03-04 17:31
Core Insights - Idexx Laboratories reported strong Q4 2025 earnings, with EPS of $3.08, an 18% increase year over year, surpassing estimates by 5.17% [2] - The company’s revenues for Q4 reached $1.09 billion, a 14% year-over-year increase, driven by growth in the Companion Animal Group and Water segments [3][4] - For 2026, Idexx forecasts revenues between $4.632 billion and $4.720 billion, indicating a growth of 7.6%-9.6% [10] Financial Performance - Q4 2025 earnings per share were $3.08, up 18% year over year, with full-year earnings of $13.08, a 22.6% increase from 2024 [2] - Quarterly revenues increased to $1.09 billion, exceeding estimates by 1.86%, with a 15% growth in the Companion Animal Group [3] - Gross profit rose 15.3% to $658.1 million, with an operating profit increase of 20.6% to $315.6 million [8] Revenue Breakdown - Companion Animal Group revenues rose 14.7% year over year to $998.5 million, while Water segment revenues increased 11.9% to $50.5 million [6] - Livestock, Poultry, and Dairy segment revenues grew 8.5% to $37.5 million, while revenues from the Other segment decreased by 0.4% to $4.1 million [6][7] Cost and Margin Analysis - Gross margin expanded by 55 basis points to 60.4%, despite a 12.7% rise in the cost of revenues [8] - Sales and marketing expenses increased by 11.3% to $167.1 million, while G&A expenses rose by 7.4% to $109 million [8] Financial Position - Cash and cash equivalents at the end of Q4 were $180.1 million, down from $288.3 million at the end of 2024 [9] - Cumulative net cash from operating activities was $1.18 billion, compared to $929 million in the prior year [9] Future Guidance - For 2026, Idexx projects EPS between $14.29 and $14.80, indicating a growth of 9-13% [10] - The Zacks Consensus Estimate for 2026 revenues is currently at $4.66 billion [10] Market Position - Idexx has a Zacks Rank of 3 (Hold), indicating an expectation of an in-line return in the coming months [13] - The company is part of the Zacks Medical - Instruments industry, which has seen mixed performance among peers [14]
IDEXX Laboratories, Inc. (IDXX) Presents at 47th Annual Raymond James Institutional Investor Conference Prepared Remarks Transcript
Seeking Alpha· 2026-03-02 16:47
Company Overview - IDEXX is focused on supporting the veterinary profession and industry, which is viewed as an exceptional long-term opportunity with a total addressable market (TAM) exceeding $45 billion [3]. Strategic Focus - The company emphasizes the importance of diagnostic testing as foundational to veterinary practice and health, stating that it is essential for prescribing therapeutics, pharmaceuticals, or specialty diets [3][4]. - Diagnostic testing is also critical for assessing the basic health status of patients, highlighting its unique role in veterinary care [4].
IDEXX Laboratories (NasdaqGS:IDXX) FY Conference Transcript
2026-03-02 15:17
Summary of IDEXX Laboratories FY Conference Call Company Overview - **Company**: IDEXX Laboratories (NasdaqGS:IDXX) - **Industry**: Veterinary diagnostics and healthcare - **Market Size**: Estimated Total Addressable Market (TAM) of over $45 billion [1] Core Strategies and Innovations - **Innovation-Driven Strategy**: Focus on developing platforms for point of care, software, and reference labs to enhance diagnostics testing [2] - **Installed Base**: Approximately 78,000 Catalyst chemistry analyzers, with recent innovations including cortisol and pancreatic lipase tests [2] - **Customer Focus**: Emphasis on providing exceptional medical care through software and data that offer clinical insights, supported by a sophisticated commercial group [3] Financial Performance and Growth - **Revenue Growth**: Targeting over 10% top-line growth over time, with U.S. growth at 10% and international growth at 12% CAGR [5][6] - **Diagnostics Revenue**: Grew 90 basis points faster than total practice revenue, with IDEXX growing 180 basis points faster than the average [9] - **Investment in Innovation**: Planned investment of approximately $1.2 billion over four years, significantly accelerated compared to previous investment timelines [16] Market Trends and Tailwinds - **Aging Pets**: Pets are living longer, leading to increased healthcare consumption; dogs and cats are living approximately 2 years longer than before [10][11] - **Pandemic Impact**: A fourfold increase in pet adoptions during the pandemic (2020-2022), leading to higher future healthcare needs [13] - **Testing Utilization**: Increased diagnostics usage as pets age, with a significant rise in healthcare consumption [12] Product Development and Offerings - **Cancer Diagnostics**: Introduction of canine lymphoma tests with high specificity (99%) and sensitivity, capable of early detection [27] - **Point of Care Innovations**: IDEXX inVue Dx analyzer has seen rapid adoption, with 6,400 units placed last year [22] - **Comprehensive Testing Panels**: Plans to expand cancer detection panels to cover a majority of common canine cancers by 2028 [28] Software and Commercial Ecosystem - **Software Solutions**: Development of a full vertical stack of software solutions to optimize veterinary practice workflows [32] - **Commercial Expansion**: Recent expansions in the U.S. and international markets to enhance customer engagement and diagnostics usage [33] Long-Term Outlook - **Growth Projections**: Anticipated long-term revenue growth of 10%+, operating margin expansion of 50-100 basis points, and EPS growth potential of 15%+ [34] - **Commitment to Innovation**: Continuous investment in innovative solutions to address veterinary practices' challenges and improve pet healthcare [34] Conclusion - IDEXX Laboratories is positioned to capitalize on significant growth opportunities in the veterinary diagnostics market, driven by innovation, a strong commercial ecosystem, and favorable market trends related to pet healthcare needs [34]
IDEXX Laboratories (NasdaqGS:IDXX) FY Earnings Call Presentation
2026-03-02 14:15
CREATING CLARITY Raymond James 47th Annual Institutional Investors Conference Jay Mazelsky President and Chief Executive Officer IDEXX Laboratories, Inc. March 2, 2026 © 2026 IDEXX Laboratories, Inc. All rights reserved. Safe Harbor Disclaimer Please refer to additional footnotes in the Appendix. © 2026 IDEXX Laboratories, Inc. All rights reserved. 2 Innovation -driven Growth Forward-Looking Statements The following presentation contains forward-looking statements within the meaning of the Private Securitie ...